UNITED LAB (03933): Marketing registration application for semaglutide injection accepted

UNITED LAB (03933) announced that the marketing registration application for the weight management indication of semaglutide injection submitted by Zhuhai United Laboratories Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been accepted by China's National Medical Products Administration. The acceptance numbers are CXSS2600179, CXSS2600180, CXSS2600181, CXSS2600182, and CXSS2600183. Semaglutide injection is a long-acting recombinant human glucagon-like peptide-1 (GLP-1) analog. It is clinically used mainly for glycemic control in patients with type 2 diabetes, long-term weight management in patients with obesity or overweight, reducing the risk of major adverse cardiovascular events in patients with obesity or overweight, and treatment of MASH (metabolic dysfunction-associated steatohepatitis) in patients with moderate to severe liver fibrosis. Administered via subcutaneous injection once weekly, it achieves significant weight loss through multiple mechanisms including appetite suppression, delayed gastric emptying, regulation of energy metabolism, and improvement of liver histology, while also providing comprehensive benefits such as reducing the risk of cardiovascular events and treating steatohepatitis with liver fibrosis, offering an efficient, convenient, and comprehensive long-term weight management solution for patients with obesity or overweight. Previously, the company submitted the marketing registration application for the diabetes indication of semaglutide injection in January 2025, which was accepted. This marketing registration application for the weight management indication further enriches the indication layout of this product and is expected to bring clinical benefits to a broader patient population. Around the GLP-1 target, the company has established a differentiated product pipeline combining innovative drugs and biosimilars, which helps enhance the company's market competitiveness in the biopharmaceutical field. In the future, the company will continue to be committed to the research and development of new products, which is expected to create greater returns for the company and its shareholders.